Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Novavax (NVAX) Cuts Full-Year Forecast as Vaccine Sales Decline
August 8, 2022 4:26 PM EDTAmerican biotechnology company Novavax (NASDAQ: NVAX) reported earnings aftermarket Monday.
The company reported a loss per share of $6.53, $12.03 worse than the analyst estimate of $5.50, and widening from the loss of $4.75 per share during the same period in 2021. Meanwhile, revenue fell year-over-year to $186... More
Novavax (NVAX) Misses Q2 EPS by $12.03, Cuts FY Guidance
August 8, 2022 4:07 PM EDTNovavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27... More
